Malaga Cove Capital’s Clearside Biomedical CLSD Stock Holding History

Malaga Cove Capital’s Portfolio CLSD Stock Details CLSD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-667	Closed	-$9.5K	–	182
2024 Q4	$9.5K	Buy	+667	New	+$11K	﹤0.01%	194

Other funds holding CLSD

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Malaga Cove Capital's CLSD Position: Q1 2025 in Review

Malaga Cove Capital sold out of Clearside Biomedical (CLSD) in Q1 2025, closing a stake of 667 shares — an estimated $9.5K sold.

Malaga Cove Capital first reported a position in CLSD in Q4 2024 and held it in 1 quarter. The position peaked at $9.5K in Q4 2024. 43 funds tracked by Wall St. Rank hold CLSD as of Q1 2025.

Malaga Cove Capital reported no remaining Clearside Biomedical position as of Q1 2025 after selling out during the quarter.
Malaga Cove Capital sold 667 Clearside Biomedical shares in Q1 2025, an estimated $9.5K.
Malaga Cove Capital first reported a position in Clearside Biomedical in Q4 2024 and held it in 1 quarter.
Malaga Cove Capital's Clearside Biomedical position peaked at $9.5K in Q4 2024.
43 funds tracked by Wall St. Rank held Clearside Biomedical as of Q1 2025.

Based on Malaga Cove Capital's 13F filing for Q1 2025, filed 9 May 2025.